Major WDTX change side-lines Albright; 101 legislation imminent; Seven-year Qualcomm and Samsung patent deal; ResMed’s IP secrets; Diversity at Meta; plus much more

Access all areas

With the latest news, analysis and data from the global IP market, an IAM subscription enables you to make effective decisions and advise with confidence. To learn more about how to secure full, unlimited access to the platform, contact [email protected]

The Long Read

While a new generation of AI tools promises to facilitate the creation of high-value IP assets, Benedikt Biechele, Brendan Sever and Bruce Rubinger warn that integrating them with professionals’ subject-matter expertise remains a major challenge. Read more here

MONDAY 25 July

USPTO proposals aimed at cracking down on perceived pharma patenting abuses risk damaging the innovation system, warns Novartis IP policy chief Corey Salsberg. Read more here

Docket Navigator data shows that the US element of the Ericsson v Apple patent battle involves four district court cases, five at the ITC and a whopping 34 inter partes review petitions. Read more here


After establishing an office in Asia, the CEO of the International Valuation Standards Council expands on plans to escalate intangible assets valuation in the region. Read more here

An economic downturn could push more operating companies to begin exploring monetisation of their IP, but they need to bear some key factors in mind when they do. Read more here

The future of the District Court for the Western District of Texas as the US’s pre-eminent patent litigation venue is uncertain after an order that will significantly reduce Judge Alan Albright’s docket. Read more here


A memorandum of understanding signed by the USPTO and WIPO to encourage ADR in SEP-related disputes is welcome, say observers, but a lot more is needed for it to happen. Read more here

In conversation with her predecessor Andrei Iancu at an event in Washington DC, USPTO Director Kathi Vidal spoke about PTAB and 101 reform, SEPs, the covid IP waiver and plenty more besides. Read more here


Qualcomm has agreed a seven-year global patent licensing deal with Samsung that will run until 2030 and which covers 6G technology, as well as 3G, 4G and 5G. Read more here

A SCOTUS petition is Teva’s final resort as it seeks to overturn a $235 million damages decision that has major IP implications for the entire pharmaceutical industry. Read more here

In an exclusive interview, Senator Thom Tillis reveals he will file legislation designed to clear-up current uncertainties relating to patent eligibility in the US “within weeks”. Read more here

FRIDAY 29 July

ResMed’s Michael Pinczuk and Keira Moore explain how deep thinking about IP strategy and communication have paid dividends for the leading medtech company. Read more here

Sanofi has out-licensed rights to its siRNA therapeutic portfolio and technology platform to a Chinese biotech as part of its “play to win” strategy. Read more here

As Meta’s Advancing Diversity Across Patent Teams programme launches, Micheal L Binns explains how the company is working to promote DEI in IP and innovation both internally and externally. Read more here


A recent decision handed down by the EPO’s Boards of Appeal may mean greater patenting opportunities for innovators using AI to help create their inventions. Read more here

Unlock unlimited access to all IAM content